Tag - CEMI

Developments

FDA approves Chembio’s dual path platform HIV-syphilis testing system

The FDA approved Chembio Diagnostics’ (NASDAQ:CEMI) dual path platform (DPP) HIV-syphilis system, a 15-minute test designed to detect HIV Type 1 and 2 antibodies and the bacteria that causes syphilis. The system...

October 2, 2020

Developments

Chembio gets FDA emergency use authorization for serological COVID-19 test

The FDA granted emergency use authorization to Chembio Diagnostics’ (NASDAQ:CEMI) dual path platform (DPP) COVID-19 system. The system is a serological point-of-care test and analyzer that provides numerical readings...

April 15, 2020

Markets

Canaccord ups Chembio Diagnostics PT to $10 from $7

Canaccord Genuity raised its price target for Chembio Diagnostics (NASDAQ:CEMI) to $10 from $7, citing the launch of its 15-minute dual path platform (DPP) COVID-19 serology test in the U.S. The stock closed at $7.16 on...

April 2, 2020

Developments

Chembio’s test for Zika, dengue and chikungunya approved by Brazil health regulator

Chembio Diagnostics’ (NASDAQ:CEMI) Zika/dengue/chikungunya multiplex test has been approved by Brazil’s health regulatory agency, ANVISA. The test uses Chembio’s DPP technology platform to detect both active infection...

April 9, 2019

Tag - CEMI

FDA approves Chembio’s dual path platform HIV-syphilis testing system

Chembio gets FDA emergency use authorization for serological COVID-19 test

Canaccord ups Chembio Diagnostics PT to $10 from $7

Chembio’s test for Zika, dengue and chikungunya approved by Brazil health regulator

General

More